Clovis Oncology

clovisoncology.com


Sector: Life Sciences

Industry: Biotechnology - Oncology

Employees: 29


Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

  

5500 Flatiron Pkwy Unit 100,

BOULDER, CO, 80301-2834 US

https://en.wikipedia.org/wiki/Clovis_Oncology 

Laboratory Scientist

NEWS

sentiment

date

title

text

http link

Grey Cat